Brand Intelligence Graph
Company Overview
About Cognito Therapeutics
Cognito Therapeutics is developing a non-pharmacological treatment for Alzheimer's disease using coordinated gamma-frequency light and sound stimulation — a technology called sensory entrainment that modulates neural oscillations implicated in the disease. The company raised an oversubscribed $105 million Series C in March 2026 led by Morningside Ventures, with its pivotal HOPE clinical trial fully enrolled and topline data expected in late 2026.
Business Model & Competitive Advantage
The Spectris device delivers 40Hz light and sound stimulation through a wearable headset in daily 1-hour home sessions, targeting the gamma brainwave dysfunction that precedes and accompanies Alzheimer's. MIT-originated research demonstrated that 40Hz sensory stimulation reduced amyloid plaques and tau tangles in preclinical models — spurring a clinical development program that now includes the fully enrolled HOPE trial, which will be the definitive test of the approach in humans.
Competitive Landscape 2025–2026
If HOPE trial results are positive, Cognito would have a novel, home-use medical device with no direct pharmacological comparator in the Alzheimer's market — an enormous commercial opportunity given the disease's prevalence and the side-effect profiles of existing pharmacological options. An FDA submission pathway follows positive topline data, making late 2026 and 2027 pivotal for the company's trajectory.
Key Differentiators
Emerging Innovator
Cognito Therapeutics is an emerging player bringing innovative solutions to the MedTech market.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
Emulate
Emulate, Inc. is a Boston-based biotechnology company that designs, manufactures, and commercializes Organ-Chip technology — micro-engineered devices lined with living human cells that replicate the m
Saluda Medical
Saluda Medical is a commercial-stage medical device company that has pioneered closed-loop neuromodulation therapy for chronic pain management. Headquartered in Macquarie Park, Australia (with US oper
Illumina
Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applicat
10x Genomics
10x Genomics was founded in 2012 in Pleasanton, California by Serge Saxonov, Ben Hindson, and Kevin Ness. The company developed the Chromium platform for single-cell RNA sequencing (scRNA-seq), enabli
ConcertAI
ConcertAI is a Boston-based company that combines artificial intelligence with real-world oncology data to accelerate cancer drug development and improve patient outcomes. Its platform integrates mult
Regeneron
Regeneron Pharmaceuticals was founded in 1988 in Tarrytown, New York by Leonard Schleifer and George Yancopoulos. The company built its reputation on the Velocimmune platform—a proprietary humanized m
Compare Cognito Therapeutics with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Cognito Therapeutics? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Cognito Therapeutics Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Cognito Therapeutics vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →